This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
by Zacks Equity Research
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
NVSPositive Net Change BMYPositive Net Change RPRXPositive Net Change CYTKNegative Net Change
biotechs medical pharmaceuticals
Regeneron (REGN) Announces Positive Data on Oncology Candidate
by Zacks Equity Research
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
REGNPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
by Kinjel Shah
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
AZNPositive Net Change RHHBYPositive Net Change PFEPositive Net Change LLYPositive Net Change
pharmaceuticals
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
HRTXPositive Net Change AQSTNegative Net Change BVSNegative Net Change CRDLPositive Net Change ACRVPositive Net Change
pharmaceuticals
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
by Zacks Equity Research
Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.
DCPHPositive Net Change ENTXNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
by Zacks Equity Research
Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.
GSKPositive Net Change BIIBPositive Net Change PTCTPositive Net Change IONSPositive Net Change LRMRPositive Net Change
biotechs pharmaceuticals
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
by Zacks Equity Research
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
PFEPositive Net Change HRTXPositive Net Change MRNSNegative Net Change ARQTNegative Net Change
biotechs medical pharmaceuticals vaccines
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
by Sundeep Ganoria
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change CVACPositive Net Change
biotechs medical pharmaceuticals vaccines
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
by Zacks Equity Research
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
KRYSNegative Net Change ANVSPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
by Zacks Equity Research
Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs immuno-therapy medical pharmaceuticals
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
by Zacks Equity Research
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
BMYPositive Net Change LGNDPositive Net Change ALXONegative Net Change
biotechnology biotechs medical pharmaceuticals
Top Research Reports for Novo Nordisk, QUALCOMM & Caterpillar
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), QUALCOMM (QCOM) and Caterpillar (CAT), as well as two micro-cap stocks CSP Inc. (CSPI) and Epsilon Energy Ltd. (EPSN).
GSKPositive Net Change QCOMNegative Net Change CATNegative Net Change NVOPositive Net Change MOPositive Net Change TDGPositive Net Change CSPINegative Net Change EPSNPositive Net Change
communications industrial-products pharmaceuticals
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
by Zacks Equity Research
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
RDYNegative Net Change ANVSPositive Net Change ALXONegative Net Change ALVOPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
by Zacks Equity Research
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.
SNYPositive Net Change AZNPositive Net Change LGNDPositive Net Change ANIPPositive Net Change
pharmaceuticals
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
by Zacks Equity Research
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
DYNPositive Net Change LGNDPositive Net Change SRPTPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.
LGNDPositive Net Change PTCTPositive Net Change ANIPPositive Net Change ANVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
by Zacks Equity Research
Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
SNYPositive Net Change MRNANegative Net Change ANIPPositive Net Change ENTXNegative Net Change
pharmaceuticals
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Roche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
NVSPositive Net Change RHHBYPositive Net Change LGNDPositive Net Change ANIPPositive Net Change
medical pharmaceuticals
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
by Zacks Equity Research
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
TEVAPositive Net Change EXELPositive Net Change LGNDPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Why Novavax (NVAX) Stock Price Appreciated 14% on Monday
by Zacks Equity Research
Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.
SNYPositive Net Change PFEPositive Net Change MRNANegative Net Change NVAXNegative Net Change
biotechs messenger-rna pharmaceuticals vaccines
AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
by Zacks Equity Research
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals
Gilead (GILD) Announces Positive Interim Results on PBC Drug
by Zacks Equity Research
Gilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.
GILDPositive Net Change LGNDPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
by Zacks Equity Research
Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
MRKPositive Net Change MRNANegative Net Change LGNDPositive Net Change ANIPPositive Net Change
pharmaceuticals
Top Research Reports for Microsoft, Eli Lilly & Costco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Eli Lilly and Company (LLY) and Costco Wholesale Corporation (COST), as well a micro-cap stock Koss Corporation (KOSS).
MSFTPositive Net Change LLYPositive Net Change UPSPositive Net Change ORLYNegative Net Change COSTNegative Net Change KOSSPositive Net Change BKNGPositive Net Change
computers pharmaceuticals retail tech-stocks
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
by Zacks Equity Research
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
INCYPositive Net Change LGNDPositive Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals